Drugs / CTL0802
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05002244 | Jul → Aug 2021 | — | Celltrion | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTL0802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05002244 ↗ |
| Known as | Rosuvastatin | “CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration” NCT05002244 ↗ |
| Route | Oral | “CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration” NCT05002244 ↗ |